Premium
T‐cell expression of CD91 – a marker of unresponsiveness to anti‐TNF therapy in rheumatoid arthritis
Author(s) -
ERIKSSON CATHARINA,
RANTAPÄÄDAHLQVIST SOLBRITT,
SUNDQVIST KARLGÖSTA
Publication year - 2010
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/j.1600-0463.2010.02677.x
Subject(s) - medicine , rheumatoid arthritis , cd14 , tumor necrosis factor alpha , cluster of differentiation , immunology , arthritis , receptor , cell , genetics , biology
Eriksson C, Rantapää‐Dahlqvist S, Sundqvist K‐G. T‐cell expression of CD91 – a marker of unresponsiveness to anti‐TNF therapy in rheumatoid arthritis. APMIS 2010; 118: 837–45. The aim of this study was to investigate the expression of thrombospondin‐1 (TSP‐1) and its receptors, lipoprotein receptor‐related protein/cluster of differentiation (CD)91, calreticulin (CRT), and CD47, on T cells and monocytes from patients with rheumatoid arthritis (RA) treated with anti‐tumor necrosis factor (TNF) therapy. The surface expression of CD91 and associated components on CD3‐ and CD14‐positive cells was examined using flow cytometry in 12 patients with established RA before and after beginning therapy and compared with that of 9 healthy controls and 12 patients with early RA treated with conventional therapies. CD3‐positive cells from anti‐TNF non‐responders showed significantly greater expression of CD91 expression than those from responders (p < 0.05) after 6 weeks and when all measurements were pooled (p < 0.001). CD91 expression on CD3‐positive cells from non‐responders to other therapies was at the same level as in healthy controls. In contrast, CD14‐positive cells showed no differences in CD91 expression between patients and controls or between responders and non‐responders to anti‐TNF therapy. The expression of TSP‐1, CRT, and CD47 showed no differences between responders and non‐responders. The results suggest T‐lymphocyte expression of CD91 to be a biomarker that signifies unresponsiveness to anti‐TNF therapy in patients with RA and may be used to identify potential responders and non‐responders.